Article Details
Retrieved on: 2024-02-13 16:37:32
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
With the return of camonsertib, Repare's deep clinical pipeline consists of four wholly owned synthetic lethal therapies.” Roche said its decision to ...
Article found on: www.outsourcing-pharma.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here